Title:
DEVELOPMENT OF NOVEL UPAR SINGLE-DOMAIN ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2023/125842
Kind Code:
A1
Abstract:
The present invention provides an anti-UPAR single-domain antibody. Specifically, a plurality of anti-UPAR single-domain antibodies are obtained by means of phage display library screening technology. The anti-UPAR single-domain antibody of the present invention can efficiently bind to UPAR, and has application prospects in the treatment of related diseases.
Inventors:
YANG LIN (CN)
YOU FENGTAO (CN)
YOU FENGTAO (CN)
Application Number:
PCT/CN2022/143550
Publication Date:
July 06, 2023
Filing Date:
December 29, 2022
Export Citation:
Assignee:
PERSONGEN BIOTHERAPEUTICS SUZHOU CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C12N5/10; C12N15/13; C12N15/63; G01N33/574; G01N33/68
Domestic Patent References:
| WO2008073312A2 | 2008-06-19 |
Foreign References:
| CN101798348A | 2010-08-11 | |||
| CN101704892A | 2010-05-12 | |||
| CN106432498A | 2017-02-22 |
Other References:
XIANG XU, CAI YUAN, WEI YING, DONATE FERNANDO, JUAREZ JOSE, PARRY GRAHAM, CHEN LIQING, MEEHAN EDWARD J., AHN RICHARD W., UGOLKOV A: "Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, vol. 9, no. 1, pages e85349, XP055198467, DOI: 10.1371/journal.pone.0085349
Attorney, Agent or Firm:
XU&PARTNERS, LLC. (CN)
Download PDF: